These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 10487657)

  • 1. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
    Alexandersen P; Riis BJ; Stakkestad JA; Delmas PD; Christiansen C
    J Clin Endocrinol Metab; 2001 Feb; 86(2):755-60. PubMed ID: 11158042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of sodium monofluorophosphate therapy on lipid and lipoprotein metabolism in postmenopausal women.
    Oral B; Ozbaşar D
    Eur J Obstet Gynecol Reprod Biol; 2003 Apr; 107(2):180-4. PubMed ID: 12648865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial.
    Reid IR; Cundy T; Grey AB; Horne A; Clearwater J; Ames R; Orr-Walker BJ; Wu F; Evans MC; Gamble GD; King A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2446-52. PubMed ID: 17440020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
    Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD; Kipshoven C; Cöster A; Umbach R
    Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
    Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
    Bone HG; Greenspan SL; McKeever C; Bell N; Davidson M; Downs RW; Emkey R; Meunier PJ; Miller SS; Mulloy AL; Recker RR; Weiss SR; Heyden N; Musliner T; Suryawanshi S; Yates AJ; Lombardi A
    J Clin Endocrinol Metab; 2000 Feb; 85(2):720-6. PubMed ID: 10690882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
    Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
    Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study.
    Ringe JD; Setnikar I
    Rheumatol Int; 2002 May; 22(1):27-32. PubMed ID: 12120908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.